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The system of plasma proteins called
complement was so-named because
it complements the activity of
antibody in the lysis of bacteria. It
has a central role in host defence
against many micro-organisms and in
the modulation of inflammatory
reactions, an activity that has been
illuminated by the study of humans
with naturally occurring deficiencies
of complement.
Complement is activated by three
pathways: the classical, alternative and
mannan-binding lectin (MBL)
pathways (Figure 1 and Table 1). The
classical pathway is primarily activated
by antibody bound to antigens
(immune complexes). The alternative
pathway is activated by the direct
binding of complement component
C3 to pathogens in the absence of
antibody. The recently discovered
MBL pathway is initiated by the
binding of MBL to mannose groups,
present on many bacterial cell walls.
All three pathways lead to the
cleavage of C3, the central component
of complement, which functions as an
opsonin, tagging pathogens and
immune complexes for recognition
and uptake, mediated by specific
complement receptors on phagocytic
cells. Subsequent activation of the
terminal complement pathway,
known as the membrane attack
complex (MAC), leads to cell lysis.
An important current focus of
complement research is the
physiological activities of
complement in vivo, on which we
will concentrate in this primer.
Complement and inflammation
Inflammation is a complex process
involving vasodilation, increased
vascular permeability and
extravasation of plasma. This is
accompanied by the adhesion of
leukocytes to vascular endothelium
and their emigration into
surrounding tissue. Complement
plays an important part in
inflammation, in helping to recruit
effector cells and in promoting the
killing and clearance of pathogens.
But complement can be both
friend and foe. In some
circumstances the activation of
complement in response to immune
complexes may cause harm: acutely
in the context of massive
complement activation occurring in
patients with overwhelming Gram-
negative bacterial sepsis, and
chronically, when an antibody
response develops in the context of
antigens that cannot be cleared.
Examples of this are infections at
anatomically-protected sites — such
as heart valves in bacterial
endocarditis — or infections by
certain viruses, such as hepatitis C,
in patients who are unable to clear
the infection. The second category
in which there is persistent
formation of immune complexes is
autoimmune disease, in which, by
definition, the antigen is a
permanent feature of the host.
An understanding of how immune
complexes cause tissue injury
developed from study of such
diseases in humans and animals, and
from the induction of experimental
immune complex disease. In these
situations, immune complexes were
shown to cause tissue injury through
activation of complement, as opsonin
(binding to complement receptors on
leukocytes) and as the source of
anaphylatoxins (stimulating leukocyte
chemotaxis and degranulation). But
the development of gene-targeted
mice with deficiencies of complement
proteins and of receptors for the Fc
part of antibodies has led to
re-appraisal of the role of complement
and antibodies in inflammatory injury.
Some studies of the formation of
immune complexes in the skin of
these animals (the Arthus reaction)
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The main pathways and components of the complement activation system.
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showed that ligation of Fc receptors
— which bind to antibodies
complexed with antigens — on mast
cells is critical for the induction of
inflammatory injury by immune
complexes, and that complement
plays little or no part. This view has
been supported by the study of the
effects of Fc receptor deficiency in
a spontaneous mouse model of an
autoimmune disease, systemic
lupus erythematosus, in which
immune complexes are prominent.
Fc receptors were shown to be
required for the development of
severe renal disease.
It is probably too early, however,
to dismiss completely the role of
complement in inflammation in
immune complex-mediated disease.
Studies of immune complex
formation in mice deficient in
complement component C5, or in the
receptor for the anaphylatoxin C5a,
demonstrated a more substantial role
for complement in the mediation of
inflammatory reactions in the lungs
and peritoneum. Similar results were
obtained in studies of peritoneal
infection in C3- and C4-deficient
mice. Complement activation was
shown to mediate the initial release
of the pro-inflammatory cytokine
TNFα by mast cells, and the
subsequent neutrophil influx.
Complement and adaptive immunity
It has been known since the seminal
experiments of Pepys in 1974 that
complement is involved in the
induction and maintenance of
antibody responses. Recently, there
has been an increasing appreciation of
the importance of the role of
complement at the interface between
innate and adaptive immunity. Here,
complement plays a part in the
localization of antigens to antigen-
presenting cells — cells specialized to
present antigens to lymphocytes and
to activate them — and to B cells,
both of which bear receptors for major
cleavage products of C3.
This activity of complement was
beautifully demonstrated by
experiments in which antibody
responses were measured in animals
immunized with antigens covalently
linked by genetic engineering to the
relevant cleavage product of C3. The
addition of increasing numbers of C3
molecules to each antigen molecule
dramatically reduced the threshold
for activation of B lymphocytes.
Evasion of complement by pathogens
One of the most fascinating aspects
of the study of complement is the
exploration of the mechanisms that
pathogens have evolved to evade
and, in some cases, exploit the
complement system. Pathogens that
cause disease are pathogenic by
virtue of their ability to escape, at
least in part, the primary mechanisms
of defence of the innate immune
system. To evade complement
pathogens have stolen and mimicked
regulatory molecules of the
complement system (Figure 2).
Complement and autoimmunity
Homozygous deficiency of classical
pathway proteins is very strongly
associated with the development of
the autoimmune disease systemic
lupus erythematosus (SLE). There is
a hierarchy of susceptibility and
severity of autoimmune disease
according to the position of the
deficient protein in the classical
pathway, with C1q deficiency showing
the highest prevalence and causing
the most severe disease. These
clinical observations imply that there
is a, so far unknown, physiological
activity of the early proteins of the
classical pathway that protects against
the development of SLE.
Some recent data point to the
discovery of a possible new
physiological activity of the
complement system that could link
complement deficiency and SLE.
There is evidence that apoptotic
cells might be the source of the
autoantigens that stimulate
autoimmunity in SLE and that C1q
might be involved in the processing
of apoptotic cells. If these findings
are confirmed, then failure of
clearance of apoptotic cells could
perhaps explain the link between
complement deficiency and SLE.
The development of C1q-deficient
mice will help to resolve this.
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Table 1
Effector activities of the complement system
Activity Complement protein Complement receptor
mediating effect
Opsonin for phagocytosis C3b, iC3b CR1, CR3
C4b CR1
C1q, MBL C1q receptor
Peptide mediators of inflammation C5a C5a receptor
C3a C3a receptor
Lytic membrane attack complex C5b, C6, C7, C8, C9
Processing and clearance of C1q C1q receptor
antigen–antibody immune complexes C3b, iC3b CR1, CR3
C4b CR1
Localization of antigen in the C3b, iC3b, C3dg CR1, CR2, CR3
form of immune complexes on 
antigen-presenting cells
Activation of B lymphocytes C3dg CR2
Clearance of apoptotic cells C1q? C1q receptor?
The activites of the complement system are
shown in the left-hand column. In the centre
are shown the complement proteins that
mediate the effects. (C3b, iC3b and C4b are
large activation products of these
complement proteins that bind covalently to
the targets of complement activation.) The
column on the right shows the receptors that
are bound by the relevant complement
ligands in the centre column.
Therapeutic inhibition of complement 
Transplantation of organs between
species that are distantly related in
phylogenetic terms — such as
humans and pigs — is followed by
rapid organ rejection, which is
mediated by massive complement
activation, caused by antibody
binding to abundant carbohydrate
epitopes on the pig tissues. Because
xenotransplantation is an attractive
option (if ethical and viral issues
permit) for overcoming the severe
shortage of human organs for
transplantation, there has been
much interest in inhibiting
complement-mediated injury to
xenotransplants. Pigs have been
developed that are transgenic for
the expression of human
complement regulatory proteins.
Organs from such animals show
significant protection from
hyperacute rejection mediated by
complement when transplanted into
non-human primates. 
A clinically-important example of
complement-mediated tissue injury
is that following infarction. For
example, the MAC might be found
in the heart following myocardial
infarction. Soluble fragments of the
complement receptor and regulatory
protein CR1 (CD35) reduce the
infarct size in experimental models
of myocardial infarction. This has yet
to be translated into clinical practice,
but complement activation in
infarction and ischaemic-reperfusion
injury remains a very attractive
target, especially if a small molecule
could be discovered with efficient
inhibitory activity for complement. 
Conclusion
When one of the authors of this
article, MW, entered complement
research he was told, possibly tongue
in cheek, by a distinguished
Professor of Medicine that
complement research was dead. We
hope this primer will persuade that
professor that the complement
system is alive and well and that the
study of complement continues to
make major and surprising
contributions to our understanding
of immunobiology.
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Figure 2
Four strategies by which pathogens use the
complement system as part of their
pathogenesis. (a) The Epstein–Barr virus
(EBV) uses a B lymphocyte receptor for
complement, CR2 (pink), to gain entry to the
cell. (Cell-surface immunoglobulin is shown
in yellow.) (b) A mycobacterium (green) fixes
a complement enzyme, C2a, to its surface.
The C2a cleaves C3, resulting in the binding
of C3b (red) to the mycobacterial surface.
The mycobacterium then enters macrophages
(blue) via C3 receptors (pink) on the cell
surface. (c) Schistosomes synthesize an
endogenous protein (purple) that mimics a
host complement regulatory protein, CD59,
and inhibits the formation of the MAC (red)
on the parasite. (d) Schistosomes absorb a
complement regulatory protein, decay
accelerating factor (DAF; green), from the
host plasma that protects against the
activation of complement by inhibiting the
formation of the C3 convertase enzyme.
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